Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study

American Journal of Gastroenterology

Volumn 95, Issue 8, 2000, Pages 2015-2022

  van Hoogstraten, H J F ^b   Vleggaar, F P ^b   Boland, G J ^b   van Steenbergen, W ^b   Griffioen, P ^b   Hop, W C J ^b   van Hattum, J ^b   van Berg Henegouwen, G B ^b   Schalm, S W ^b   van Buuren, H R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUDESONIDE; CORTICOTROPIN; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; PRASTERONE; PREDNISONE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL;

ADRENAL CORTEX HORMONES; ADRENOCORTICOTROPIC HORMONE; ADULT; ALKALINE PHOSPHATASE; ANTI-INFLAMMATORY AGENTS; BILE; BUDESONIDE; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; PRURITUS; URSODEOXYCHOLIC ACID;

EID: 0033880057     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)01059-5     Document Type: Article

References (39)

1. Primary sclerosing cholangitis
2. Primary sclerosing cholangitis: Evolving concepts in diagnosis and treatment
3. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis
4. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis
5. Role of immune factors in the pathogenesis of primary sclerosing cholangitis
6. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases
7. Neutrophil autoantibodies: A genetic marker in primary sclerosing cholangitis and ulcerative colitis
8. Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: A comparison of the alkaline phosphatase and immunofluorescent techniques
9. Association of primary sclerosing cholangitis with HLA-B8
10. Association of primary sclerosing cholangitis with HLA-DRw52a
11. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis
12. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis
13. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis
14. Features of autoimmune hepatitis in primary sclerosing cholangitis: An evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis
15. Positive corticosteroid response in early sclerosing cholangitis
16. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis
17. Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease
18. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid
19. A comparison of budesonide with prednisolone for active Crohn's disease
20. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period
21. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial
22. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses
23. Ursodiol for primary sclerosing cholangitis
24. Improving the quality of reporting of randomized controlled trials. The CONSORT statement
25. Primary sclerosing cholangitis. Findings on cholangiography and pancreatography
26. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis
27. Transection of the oesophagus for bleeding oesophageal varices
28. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: A 1-year randomized, placebo-controlled study
29. Oral budesonide for treatment of autoimmune chronic active hepatitis
30. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss
31. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes
32. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease
33. Pharmacokinetic and metabolism of budesonide, a selective glucocorticoid
34. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group
35. Prospective trial of penicillamine in primary sclerosing cholangitis
36. A controlled trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis
37. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis
38. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study
39. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis. Results of an open-label preliminary trial